Open Access Original article

Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells

Aaron Tan12, Yasmin Farhatnia1, Debbie Goh12, Natasha G12, Achala de Mel1, Jing Lim3, Swee-Hin Teoh3, Andrey V Malkovskiy4, Reema Chawla1, Jayakumar Rajadas4, Brian G Cousins1, Michael R Hamblin567, Mohammad S Alavijeh8 and Alexander M Seifalian19*

Author Affiliations

1 Centre for Nanotechnology & Regenerative Medicine, UCL Division of Surgery & Interventional Science, University College London, London, UK

2 UCL Medical School, University College London, London, UK

3 Division of Bioengineering, School of Chemical & Biomedical Engineering, Nanyang Technological University, Singapore, Singapore

4 Biomaterials & Advanced Drug Delivery Laboratory, School of Medicine, Stanford University, Stanford, CA, USA

5 Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA

6 Department of Dermatology, Harvard Medical School, Boston, MA, USA

7 Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA, USA

8 Pharmidex Pharmaceutical Services Ltd, London, UK

9 Royal Free London NHS Foundation Trust, London, UK

For all author emails, please log on.

Biointerphases 2013, 8:23  doi:10.1186/1559-4106-8-23

Published: 23 August 2013


An unmet need exists for the development of next-generation multifunctional nanocomposite materials for biomedical applications, particularly in the field of cardiovascular regenerative biology. Herein, we describe the preparation and characterization of a novel polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer with covalently attached anti-CD34 antibodies to enhance capture of circulating endothelial progenitor cells (EPC). This material may be used as a new coating for bare metal stents used after balloon angioplasty to improve re-endothelialization. Biophysical characterization techniques were used to assess POSS-PCU and its subsequent functionalization with anti-CD34 antibodies. Results indicated successful covalent attachment of anti-CD34 antibodies on the surface of POSS-PCU leading to an increased propensity for EPC capture, whilst maintaining in vitro biocompatibility and hemocompatibility. POSS-PCU has already been used in 3 first-in-man studies, as a bypass graft, lacrimal duct and a bioartificial trachea. We therefore postulate that its superior biocompatibility and unique biophysical properties would render it an ideal candidate for coating medical devices, with stents as a prime example. Taken together, anti-CD34 functionalized POSS-PCU could form the basis of a nano-inspired polymer platform for the next generation stent coatings.

POSS-PCU; Stent coatings; Anti-CD34 antibody; Endothelialization; Endothelial progenitor cell capture; Nanotechnology; Regenerative medicine; Biomaterials